The Thermodynamic Logic of Danger Theory
Proposes context-dependent immune activation is 10-100x more energy efficient than classical models.
2024|
Building AI-powered medical tools from crisis, science, and invention
From systems architect to healthcare innovator, Ken Mendoza's journey began in the trenches of Silicon Valley tech companies, where he learned to build scalable systems and navigate the complex path from innovation to IPO. His technical foundation spans 25+ years of AI and software development, including leadership roles that culminated in a successful NASDAQ public offering.
The defining moment came during a deeply personal health crisis experienced by Ken's soulmate and the love of his life, Toni. Her medical journey—a relentless series of more than a hundred complex tests involving numerous specialists—ultimately led to the diagnoses of both a brain tumor and autoimmune disease, conditions that had previously gone undetected. This transformative experience exposed fundamental gaps in medical information management and care coordination, inspiring Ken's mission to revolutionize healthcare through AI and fueling the creation of MedAdvocate.
Today, Ken operates at the unique intersection of deep biomedical science, scalable software architecture, and defensible intellectual property. His work spans from computational immunology research exploring Polly Matzinger's Danger Theory to building AI-powered clinical tools.
With 5 patents in proteomics and extensive experience in drug target identification, Ken brings a rare combination of scientific rigor, technical execution, and venture leadership to the next generation of healthcare innovation.
AI-Powered Medical Journey Companion built from lived experience navigating complex care. Consolidates symptoms, tests, and medical records into AI-accessible insights.
Learn MoreComputational Immunology Research Platform exploring Polly Matzinger's Danger Theory and its implications for context-aware clinical AI. Bridging biological pattern recognition with machine learning efficiency.
Learn MoreSaaS & AI Automation Innovation Lab co-founded to develop commercial AI products and build a protected innovation portfolio. Focus on business automation and intelligent systems.
Learn MoreArbor Vita Corporation (2001-2008)
Extensive portfolio of intellectual property developed during pioneering work in computational proteomics, establishing foundational technologies for AI-driven drug discovery and molecular analysis platforms.
Proposes context-dependent immune activation is 10-100x more energy efficient than classical models.
2024Traces the paradigm shift in immunology from self/non-self recognition to danger-based activation models.
2024Analyzes the "low road" neural pathway for high-contrast visual processing and its implications for AI perception.
2023Created AI-powered medical journey platform
2025-PresentBuilding the next generation of commercial AI products with protected innovation portfolio
2024-PresentPursued independent consulting and creative ventures while maintaining expertise in technology and biomedical innovation
2008-2024Arbor Vita Corporation
Developed 5 patents in proteomics and led drug target identification programs
2001-2008Digital Lava Inc.
Led innovation resulting in successful NASDAQ IPO
1997-2001Are you an investor or strategic partner seeking to drive innovation in healthcare AI and biomedical technology? Join Ken Mendoza—AI Healthcare Founder, Biomedical Innovator, and Technology & IP Leader—in building the next generation of medical solutions. Let's shape the future of medicine together through impactful collaboration and sustainable growth.